GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14th, 2019 at 8:35 am ET in New York.
A live audio webcast of the presentation can be accessible by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the company's website following the event.
About AGTC AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients sufferig from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM CNGB3 & ACHM CNGA3) and X-linked retinoschisis (XLRS). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS) and other ophthalmology and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR Contacts: David Carey (IR) or Glenn Silver (PR) Lazar Partners Ltd. T: (212) 867-1768 or (646) 871-8485 [email protected] or [email protected]
